vs

Side-by-side financial comparison of Core Laboratories Inc. (CLB) and Vertex, Inc. (VERX). Click either name above to swap in a different company.

Vertex, Inc. is the larger business by last-quarter revenue ($194.7M vs $121.8M, roughly 1.6× Core Laboratories Inc.). Core Laboratories Inc. runs the higher net margin — 4.2% vs -3.6%, a 7.8% gap on every dollar of revenue. On growth, Vertex, Inc. posted the faster year-over-year revenue change (9.1% vs -1.4%). Over the past eight quarters, Vertex, Inc.'s revenue compounded faster (11.4% CAGR vs -3.4%).

Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.

Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.

CLB vs VERX — Head-to-Head

Bigger by revenue
VERX
VERX
1.6× larger
VERX
$194.7M
$121.8M
CLB
Growing faster (revenue YoY)
VERX
VERX
+10.6% gap
VERX
9.1%
-1.4%
CLB
Higher net margin
CLB
CLB
7.8% more per $
CLB
4.2%
-3.6%
VERX
Faster 2-yr revenue CAGR
VERX
VERX
Annualised
VERX
11.4%
-3.4%
CLB

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CLB
CLB
VERX
VERX
Revenue
$121.8M
$194.7M
Net Profit
$5.1M
$-7.0M
Gross Margin
64.8%
Operating Margin
1.5%
-1.3%
Net Margin
4.2%
-3.6%
Revenue YoY
-1.4%
9.1%
Net Profit YoY
89.7%
EPS (diluted)
$0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLB
CLB
VERX
VERX
Q1 26
$121.8M
Q4 25
$138.3M
$194.7M
Q3 25
$134.5M
$192.1M
Q2 25
$130.2M
$184.6M
Q1 25
$123.6M
$177.1M
Q4 24
$129.2M
$178.5M
Q3 24
$134.4M
$170.4M
Q2 24
$130.6M
$161.1M
Net Profit
CLB
CLB
VERX
VERX
Q1 26
$5.1M
Q4 25
$4.9M
$-7.0M
Q3 25
$14.2M
$4.0M
Q2 25
$10.6M
$-961.0K
Q1 25
$-154.0K
$11.1M
Q4 24
$7.4M
$-67.8M
Q3 24
$11.7M
$7.2M
Q2 24
$9.0M
$5.2M
Gross Margin
CLB
CLB
VERX
VERX
Q1 26
Q4 25
20.8%
64.8%
Q3 25
22.0%
63.1%
Q2 25
20.3%
65.7%
Q1 25
19.5%
63.8%
Q4 24
17.8%
65.6%
Q3 24
20.5%
64.8%
Q2 24
21.2%
63.7%
Operating Margin
CLB
CLB
VERX
VERX
Q1 26
1.5%
Q4 25
11.5%
-1.3%
Q3 25
15.6%
2.2%
Q2 25
11.7%
-2.1%
Q1 25
3.6%
2.5%
Q4 24
11.0%
-7.3%
Q3 24
14.7%
2.9%
Q2 24
12.3%
4.7%
Net Margin
CLB
CLB
VERX
VERX
Q1 26
4.2%
Q4 25
3.6%
-3.6%
Q3 25
10.6%
2.1%
Q2 25
8.2%
-0.5%
Q1 25
-0.1%
6.3%
Q4 24
5.7%
-38.0%
Q3 24
8.7%
4.2%
Q2 24
6.9%
3.2%
EPS (diluted)
CLB
CLB
VERX
VERX
Q1 26
$0.11
Q4 25
$0.11
Q3 25
$0.30
Q2 25
$0.22
Q1 25
$0.00
Q4 24
$0.15
Q3 24
$0.25
Q2 24
$0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLB
CLB
VERX
VERX
Cash + ST InvestmentsLiquidity on hand
$22.8M
$314.0M
Total DebtLower is stronger
$337.5M
Stockholders' EquityBook value
$275.1M
$258.9M
Total Assets
$587.7M
$1.3B
Debt / EquityLower = less leverage
1.30×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLB
CLB
VERX
VERX
Q1 26
$22.8M
Q4 25
$22.7M
$314.0M
Q3 25
$25.6M
$313.5M
Q2 25
$31.2M
$284.4M
Q1 25
$22.1M
$270.4M
Q4 24
$19.2M
$296.1M
Q3 24
$21.5M
$279.0M
Q2 24
$17.7M
$325.5M
Total Debt
CLB
CLB
VERX
VERX
Q1 26
Q4 25
$110.3M
$337.5M
Q3 25
$114.1M
$336.9M
Q2 25
$124.6M
$336.3M
Q1 25
$124.4M
$335.8M
Q4 24
$126.1M
$335.2M
Q3 24
$139.9M
$334.7M
Q2 24
$147.6M
$334.1M
Stockholders' Equity
CLB
CLB
VERX
VERX
Q1 26
$275.1M
Q4 25
$266.0M
$258.9M
Q3 25
$271.3M
$264.5M
Q2 25
$261.3M
$248.0M
Q1 25
$253.4M
$200.5M
Q4 24
$246.6M
$179.4M
Q3 24
$250.7M
$259.0M
Q2 24
$240.3M
$233.1M
Total Assets
CLB
CLB
VERX
VERX
Q1 26
$587.7M
Q4 25
$584.0M
$1.3B
Q3 25
$591.4M
$1.2B
Q2 25
$602.1M
$1.2B
Q1 25
$591.5M
$1.2B
Q4 24
$585.1M
$1.2B
Q3 24
$600.5M
$1.2B
Q2 24
$597.8M
$1.0B
Debt / Equity
CLB
CLB
VERX
VERX
Q1 26
Q4 25
0.41×
1.30×
Q3 25
0.42×
1.27×
Q2 25
0.48×
1.36×
Q1 25
0.49×
1.67×
Q4 24
0.51×
1.87×
Q3 24
0.56×
1.29×
Q2 24
0.61×
1.43×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLB
CLB
VERX
VERX
Operating Cash FlowLast quarter
$4.0M
$42.3M
Free Cash FlowOCF − Capex
$517.0K
FCF MarginFCF / Revenue
0.4%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
0.77×
TTM Free Cash FlowTrailing 4 quarters
$22.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLB
CLB
VERX
VERX
Q1 26
$4.0M
Q4 25
$7.9M
$42.3M
Q3 25
$8.5M
$62.5M
Q2 25
$13.9M
$46.0M
Q1 25
$6.7M
$14.8M
Q4 24
$20.6M
$41.1M
Q3 24
$13.1M
$41.4M
Q2 24
$17.1M
$57.7M
Free Cash Flow
CLB
CLB
VERX
VERX
Q1 26
$517.0K
Q4 25
$5.0M
Q3 25
$6.5M
Q2 25
$10.4M
Q1 25
$3.9M
Q4 24
$17.4M
Q3 24
$10.4M
$-24.3M
Q2 24
$14.3M
FCF Margin
CLB
CLB
VERX
VERX
Q1 26
0.4%
Q4 25
3.6%
Q3 25
4.8%
Q2 25
8.0%
Q1 25
3.1%
Q4 24
13.4%
Q3 24
7.7%
-14.2%
Q2 24
10.9%
Capex Intensity
CLB
CLB
VERX
VERX
Q1 26
Q4 25
2.1%
Q3 25
1.5%
Q2 25
2.7%
Q1 25
2.3%
Q4 24
2.5%
Q3 24
2.0%
38.5%
Q2 24
2.2%
Cash Conversion
CLB
CLB
VERX
VERX
Q1 26
0.77×
Q4 25
1.61×
Q3 25
0.60×
15.44×
Q2 25
1.31×
Q1 25
1.33×
Q4 24
2.78×
Q3 24
1.12×
5.73×
Q2 24
1.90×
11.18×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLB
CLB

Segment breakdown not available.

VERX
VERX

Cloud Subscriptions$94.6M49%
Software Licenses$71.6M37%
Service Other$28.5M15%

Related Comparisons